DOCSLIB.ORG

Particle Therapy Optimized Business Operations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Particle Therapy Optimized Business Operations Particle Therapy Optimized business operations Solutions working in concert to create efficient workflows Particle Therapy Optimized business operations Establishing or growing a particle therapy practice that operates securely in a multi-vendor, multi-modality requires as much attention to the components forming environment. Elekta, a leader in particle therapy from the integrated whole as it does in selecting an appro- the modality’s beginning, helps the customer put it all priate treatment machine. Beyond technology, there’s together. From XiO® planning, MOSAIQ® information efficiency. It’s how the treatment planning system and its management and Clarity™ soft tissue visualization to components, patient positioning and immobilization patient-friendly support equipment and expert devices, and information management technology consultative services, Elekta works with the center work together to create the best possible workflow to build a world-class particle therapy service. “The Elekta team brings significant expertise in proton therapy and radiation oncology with their software solution and, more importantly, the associated service. Elekta shares our vision of making the OIS the central hub for the entire therapy workflow, and together we can make this happen. This will provide significant benefits to our physician partners, hospital partners and their patients.” Niek Schreuder Senior Vice President of Medical Physics & Technology ProCure Treatment Centers “The shared vision and effort of a group of vendors, including Elekta, made the process of creating a proton therapy center manageable and the outcome a reality. Elekta professionals integrated proton support into our existing IT implementation, allowing us to extend our current chartless radiation therapy environment to the new proton center.” James D. Cox, MD Professor and Head, Division of Radiation Oncology M. D. Anderson Cancer Center Oncology Information Respiratory Motion Image Guidance System (OIS) Management Clarity™ takes soft tissue The key to achieving patient care Active Breathing Coordinator is visualization to entirely new levels objectives is consolidation of all a simple, vendor-independent for PT treatments. Easy to learn and aspects of the oncology service solution for pausing a patient’s use, Clarity is capable of integrating through a single OIS. MOSAIQ® is breath at inhalation for a short with any PT workflow and treatment used in over 3,000 oncology centers period, during radiation delivery. delivery platform. Clarity’s hybrid globally and more oncology patients’ This breath hold technique has imaging technology delivers superior records are managed using MOSAIQ helped clinicians dramatically soft tissue visualization for CT-Sim, than any other commercial OIS— reduce margins for tumors assisting with contouring during making it the most comprehensive impacted by respiratory motion. PT simulation and planning. In and widely used system. MOSAIQ addition, Clarity provides high delivers quality software solutions Patient Positioning spatial accuracy and speed for that are designed to meet the and Immobilization daily setup and positioning as well continually evolving needs of A requirement for the success of as a path to intra-fractional, non- oncology departments. This dynamic rigorous particle therapy treatment invasive anatomy-based real-time and pragmatic development modalities is precise patient tracking1. Based on patented medical approach has led to the adaptation of positioning and immobilization, imaging technology, Clarity is a safe MOSAIQ for particle therapy—now from planning to treatment. and gentle approach to providing in clinical use. In fact, MOSAIQ is BodyFIX® and Fraxion, non-invasive enhanced soft tissue image guidance the principal image-enabled chart of immobilization and positioning for PT. the particle therapy clinic. systems, provide accurate and reproducible patient positioning Data Visualization Treatment Planning for particle therapy. and Analysis Elekta has worked to enhance ANALYTIQ™ is a data visualization particle therapy planning solutions Service and Support and analysis tool, which creates an since 1998. Today, XiO®, Focal 4D™ To maximize the clinical and interactive, graphical environment to and Atlas-based Autosegmentation financial potential of oncology explore, segment and analyze large (ABAS) deliver comprehensive management solutions requires volumes of practice management planning functionalities that address centers to have or gain an in related data. Direct data visualization a range of clinical needs. In addition, depth understanding of the enables quick discovery of trends, the integrated planning capability technology they use and how they anomalies and relations and supports several treatment use it. STRATEGIQ® consultative immediate exploration of their modalities, including broad services provide a comprehensive, root causes. Upon completion of beam, pencil beam scanning and accelerated approach to help an analysis, a perspective can be continuous scanning together with facilities fully utilize their Elekta IT exported to other types of programs conventional radiation therapy. XiO, solutions—improving the facility’s – spreadsheets, statistical packages in particular, provides you with a operational and clinical function. and word processors – for additional comprehensive 3D IMRT planning Fundamentally, STRATEGIQ analysis, electronic distribution or platform. It includes automated tools services are designed to help data archiving. to reduce planning time and robust facilities adapt rapidly to change dose calculation algorithms for and sustain value in the prevention, highly precise plans. diagnosis, treatment, research and follow-up of cancer patients. NOTES/DOCUMENTS NOTES/DOCUMENTS/IMAGES NOTES/DOCUMENTS/IMAGES SCHEDULING SCHEDULING MOSAIQ®2 PARTICLE THERAPY3 MOSAIQ® RTP4 NOTES/ IMAGES REFERRAL/ PATIENT SETUP TREATMENT PLANNING MILLING DEVICE PRE-TREATMENT PATIENT POSITIONING TREATMENT REPORTING CONSULTATION Clarity™ Hybrid Imaging XiO® image courtesy of .decimal, Inc SET-UP/QA BodyFIX®/Fraxion™/Active Real Time Target & ANALYSIS CT/Clarity™ Fusion Clarity™ Breathing Coordinator™/Clarity™ Tracking1/Clarity PLANNING / IMAGE GUIDANCE / RADIATION DELIVERY ARCHIVED PLANS sent via. DICOM RT to MOSAIQ® DATA DIRECTOR DAILY 3D IMAGING Clarity™ STRATEGIQ® 1Clarity real time tracking is a works in progress. 2SEQUENCER is MOSAIQ’s verify & record module. 3MOSAIQ/SEQUENCER support of carbon ion therapy is a works in progress. 4MOSAIQ RTP is a works in progress. Why Elekta Particle Therapy? End-to-end solution Connectivity Multi-modality Enhanced patient experience Reduced clinical risk Maximized return on investment (ROI) A human care company, Elekta pioneers significant innovations and clinical solutions for treating cancer and brain disorders. Elekta provides intelligent and resource-efficient technologies that improve, prolong and save patient lives. We go beyond collaboration seeking long-term relationships built on trust with a shared vision, offering confidence to healthcare providers and their patients. www.elekta.com Human Care Makes the Future Possible Corporate Head Office: Regional Sales, Marketing and Service: Elekta AB (publ) North America Europe, Middle East, Africa, Box 7593, SE-103 93 Stockholm, Eastern Europe, Latin America Sweden Tel +1 770 300 9725 Tel +46 8 587 254 00 Tel +46 8 587 254 00 Fax +1 770 448 6338 Fax +46 8 587 255 00 Fax +46 8 587 255 00 [email protected] [email protected] [email protected] Document 4513 no. 371 0721 11:10 © 2010 Elekta AB (publ). All mentioned trademarks and registered trademarks are the property of the Elekta All Group. rights reserved. No part of this document may be reproduced in any form without written permission from the copyright holder..
Load more

Recommended publications
  • Targeted Radiotherapeutics from 'Bench-To-Bedside'
    RadiochemistRy in switzeRland CHIMIA 2020, 74, No. 12 939 doi:10.2533/chimia.2020.939 Chimia 74 (2020) 939–945 © C. Müller, M. Béhé, S. Geistlich, N. P. van der Meulen, R. Schibli Targeted Radiotherapeutics from ‘Bench-to-Bedside’ Cristina Müllera, Martin Béhéa, Susanne Geistlicha, Nicholas P. van der Meulenab, and Roger Schibli*ac Abstract: The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for success- ful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affin- ity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastruc- ture for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type labora- tories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides, exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while investigating and characterizing new targeting structures and optimizing these aspects for translational research on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising candidates are translated to clinics for ‘first-in-human’ studies.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]
  • Protocol for Heavy Charged-Particle Therapy Beam Dosimetry
    AAPM REPORT NO. 16 PROTOCOL FOR HEAVY CHARGED-PARTICLE THERAPY BEAM DOSIMETRY Published by the American Institute of Physics for the American Association of Physicists in Medicine AAPM REPORT NO. 16 PROTOCOL FOR HEAVY CHARGED-PARTICLE THERAPY BEAM DOSIMETRY A REPORT OF TASK GROUP 20 RADIATION THERAPY COMMITTEE AMERICAN ASSOCIATION OF PHYSICISTS IN MEDICINE John T. Lyman, Lawrence Berkeley Laboratory, Chairman Miguel Awschalom, Fermi National Accelerator Laboratory Peter Berardo, Lockheed Software Technology Center, Austin TX Hans Bicchsel, 1211 22nd Avenue E., Capitol Hill, Seattle WA George T. Y. Chen, University of Chicago/Michael Reese Hospital John Dicello, Clarkson University Peter Fessenden, Stanford University Michael Goitein, Massachusetts General Hospital Gabrial Lam, TRlUMF, Vancouver, British Columbia Joseph C. McDonald, Battelle Northwest Laboratories Alfred Ft. Smith, University of Pennsylvania Randall Ten Haken, University of Michigan Hospital Lynn Verhey, Massachusetts General Hospital Sandra Zink, National Cancer Institute April 1986 Published for the American Association of Physicists in Medicine by the American Institute of Physics Further copies of this report may be obtained from Executive Secretary American Association of Physicists in Medicine 335 E. 45 Street New York. NY 10017 Library of Congress Catalog Card Number: 86-71345 International Standard Book Number: 0-88318-500-8 International Standard Serial Number: 0271-7344 Copyright © 1986 by the American Association of Physicists in Medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Published by the American Institute of Physics, Inc., 335 East 45 Street, New York, New York 10017 Printed in the United States of America Contents 1 Introduction 1 2 Heavy Charged-Particle Beams 3 2.1 ParticleTypes .........................
    [Show full text]
  • Present Status of Fast Neutron Therapy Survey of the Clinical Data and of the Clinical Research Programmes
    PRESENT STATUS OF FAST NEUTRON THERAPY SURVEY OF THE CLINICAL DATA AND OF THE CLINICAL RESEARCH PROGRAMMES Andre Wambersie and Francoise Richard Universite Catholique de Louvain, Unite de Radiotherapie, Neutron- et CurietheVapie, Cliniques Universitaires St-Luc, 1200-Brussels, Belgium. Abstract The clinical results reported from the different neutron therapy centres, in USA, Europe and Asia, are reviewed. Fast neutrons were proven to be superior to photons for locally extended inoperable salivary gland tumours. The reported overall local control rates are 67 % and 24 % respectively. Paranasal sinuses and some tumours of the head and neck area, especially extended tumours with large fixed lymph nodes, are also indications for neutrons. By contrast, the results obtained for brain tumours were, in general, disappointing. Neutrons were shown to bring a benefit in the treatment of well differentiated slowly growing soft tissue sarcomas. The reported overall local control rates are 53 % and 38 % after neutron and photon irradiation respectively. Better results, after neutron irradiation, were also reported for bone- and chondrosarcomas. The reported local control rates are 54 % for osteosarcomas and 49 % for chondrosarcomas after neutron irradiation; the corresponding values are 21 % and 33 % respectively after photon irradiation. For locally extended prostatic adenocarcinoma, the superiority of mixed schedule (neutrons + photons) was demonstrated by a RTOG randomized trial (local control rates 77% for mixed schedule compared to 31 % for photons). Neutrons were also shown to be useful for palliative treatment of melanomas. Further studies are needed in order to definitively evaluate the benefit of fast neutrons for other localisations such as uterine cervix, bladder, and rectum.
    [Show full text]
  • Efficacy and Toxicity of Particle Radiotherapy in WHO Grade II and Grade III Meningiomas: a Systematic Review
    NEUROSURGICAL FOCUS Neurosurg Focus 46 (6):E12, 2019 Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review *Adela Wu, MD,1 Michael C. Jin, BS,2 Antonio Meola, MD, PhD,1 Hong-nei Wong, MLIS, DVM,3 and Steven D. Chang, MD1 1Department of Neurosurgery, Stanford Health Care, Palo Alto; 2Stanford University School of Medicine, Stanford; and 3Lane Medical Library, Stanford Medicine, Palo Alto, California OBJECTIVE Adjuvant radiotherapy has become a common addition to the management of high-grade meningiomas, as immediate treatment with radiation following resection has been associated with significantly improved outcomes. Recent investigations into particle therapy have expanded into the management of high-risk meningiomas. Here, the authors systematically review studies on the efficacy and utility of particle-based radiotherapy in the management of high-grade meningioma. METHODS A literature search was developed by first defining the population, intervention, comparison, outcomes, and study design (PICOS). A search strategy was designed for each of three electronic databases: PubMed, Embase, and Scopus. Data extraction was conducted in accordance with the PRISMA guidelines. Outcomes of interest included local disease control, overall survival, and toxicity, which were compared with historical data on photon-based therapies. RESULTS Eleven retrospective studies including 240 patients with atypical (WHO grade II) and anaplastic (WHO grade III) meningioma undergoing particle radiation therapy were identified. Five of the 11 studies included in this systematic review focused specifically on WHO grade II and III meningiomas; the others also included WHO grade I meningioma. Across all of the studies, the median follow-up ranged from 6 to 145 months.
    [Show full text]
  • Radiation Therapy in Adult Soft Tissue Sarcoma—Current Knowledge and Future Directions: a Review and Expert Opinion
    cancers Review Radiation Therapy in Adult Soft Tissue Sarcoma—Current Knowledge and Future Directions: A Review and Expert Opinion Falk Roeder Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Landeskrankenhaus, Salzburg 5020, Austria; [email protected]; Tel.: +43-57-255-58923 Received: 1 October 2020; Accepted: 29 October 2020; Published: 3 November 2020 Simple Summary: Radiation therapy (RT) is an integral part of the treatment of adult soft-tissue sarcomas (STS). Although mainly used as perioperative therapy to increase local control in resectable STS with high risk features, it also plays an increasing role in the treatment of non-resectable primary tumors, oligometastatic situations, or for palliation. This review summarizes the current evidence for RT in adult STS including typical indications, outcomes, side effects, dose and fractionation regimens, and target volume definitions based on tumor localization and risk factors. It covers the different overall treatment approaches including RT either as part of a multimodal treatment strategy or as a sole treatment and is accompanied by a summary on ongoing clinical research pointing at future directions of RT in STS. Abstract: Radiation therapy (RT) is an integral part of the treatment of adult soft-tissue sarcomas (STS). Although mainly used as perioperative therapy to increase local control in resectable STS with high risk features, it also plays an increasing role in the treatment of non-resectable primary tumors, oligometastatic situations, or for palliation. Modern radiation techniques, like intensity-modulated, image-guided, or stereotactic body RT, as well as special applications like intraoperative RT, brachytherapy, or particle therapy, have widened the therapeutic window allowing either dose escalation with improved efficacy or reduction of side effects with improved functional outcome.
    [Show full text]
  • Toward Intensity Modulated Treatment on the University of Washington Clinical Neutron Therapy System
    AAMD 43rd Annual Meeting June 17 – 21, 2018 Toward Intensity Modulated Treatment on the University of Washington Clinical Neutron Therapy System Landon Wootton June 20th, 2018 AAMD 43rd Annual Meeting Austin, Texas Disclosures . This presentation does not constitute an endorsement of any product (for your neutron planning needs or otherwise). No funding sources or conflicts of interest to disclose. 1 AAMD 43rd Annual Meeting June 17 – 21, 2018 Learner Outcomes . Familiarity with the historical use and current indications for treatment with neutron therapy. Understand the design and function of the University of Washington Clinical Neutron Therapy System (CNTS). Awareness of different beam modeling approaches for the CNTS neutron beam. CNTS History at University of Washington • 1973-1984 – Laboratory based neutron beam – 22 MeV deuterons incident on a beryllium target – Fixed horizontal beam – Magnetic rectangular collimation – No wedges – Resulting beam depth dose characteristics similar to Co-60 – 604 Patient Treated 2 AAMD 43rd Annual Meeting June 17 – 21, 2018 CNTS History at University of Washington . 1979 – Installation of dedicated hospital based neutron treatment system begins as part of NIH grant. – Gantry with full range of rotational motion, collimator and built in wedges, flattening filter, MLCs. 1984 – October 19th: first patient treatment – >3000 patients treated since Radiation Biology • Neutrons are indirectly ionizing, and damage DNA through the secondary particles they produce. – Mostly low-energy, high-LET protons as well as some heavier ions. – Compare to photons/protons which primarily generate electrons. • This affords neutrons unique radiobiological advantages. – Can overcome radiation resistance of hypoxic cells. – Dense ionization results in more fatal cellular damage per dose.
    [Show full text]
  • Planning and Implementing a Swiss Radio-Oncology Network
    Chair Secretary PROTON Michael Goitein Ph. D. Daniel Miller Ph. D. THERAPY Department of Radiation Oncology Department of Radiation Medicine C O- Massachusetts General Hospital Loma Linda University Medical Center OPERATIVE Boston MA 02114 Loma Linda CA 92354 G ROUP (617) 724 - 9529 (909) 824 - 4197 (617) 724 - 9532 Fax (909) 824 - 4083 Fax ABSTRACTS of the XXIV PTCOG MEETING held in Detroit, Michigan, USA April 24-26 1996 1 INDEX Page PTCOG Focus Session I: Comparative treatment planning of nasopharyngeal tumors PTCOG nasopharynx treatment planning intercomparison. 5 A. Smith PTCOG Focus Session II: Proton theray clinical studies Proton therapy in 1996: a world wide perspective. 6 J. M. Sisterson Arteriovenous malformations: the NAC experience. 6 F. Vernimmen, J. Wilson, D. Jones, N. Schreuder, E. De Kock, J. Symons Preliminary results of carbon-ion therapy at NIRS. 6 H. Tsujii, J. Mizoe, T. Miyamoto, S. Morita, M. Mukai, T. Nakano, H. Kato, T. Kamada, K. Morita Proton radiation therapy for orbital and parameningeal rhabdomyosarcoma. 7 E. B. Hug, J.A. Adams, J. E. Munzenrider Conformal radiation therapy for retinoblastoma: comparison of various 3D proton plans. 8 M. Krengli, J. A Adams, E. B Hug PTCOG Focus Session III Radiotherapy in the treatment of prostate cancer: neutrons, protons or photons? An analysis of acute and late toxicity in a randomized study of pion vs. photon irradiation 9 for stage T3/4 prostate cancer. T. Pickles, G. Goodman, M. Dimitrov, G. Duncan, C. Fryer, P. Graham, M. McKenzie, J. Morris, D. Rheaume, I. Syndikus With conformal photon irradiation, who needs particles? 10 J.
    [Show full text]
  • Particle Therapy an Advanced Form of Radiation Treatment for Cancer
    Particle Therapy An advanced form of radiation Proposed integrated treatment for national network Proton Carbon/Proton cancer facility facility Particle therapy is similar to traditional forms of In other countries, particle therapy is recommended radiation therapy, but it offers an even more for some patients with difficult-to-treat cancers. targeted approach. This means that the risk of harm to tissue around a tumour is lower than Proton therapy has been approved overseas for use with standard radiation. Instead of x-rays used in in children, adolescents and young adults, who are standard radiation, particle therapy uses protons or more at risk of long-term side effects from heavy ions such as carbon, which have an improved traditional treatment approaches. ability to kill cancer cells. Particle therapy, like It minimises the radiation to critical standard radiation, is painless and delivers radiation structures in the body and limits the through the skin. And the particles release their risks of long-term side effects. energy at the site of the tumour more precisely. This makes the treatment suitable for cancers near critical parts of the body, such as the eyes, brain and spinal cord. As well as being very precise, carbon ions deposit more energy to the tumour than protons or standard radiation. This means carbon ion therapy can be more effective at killing tumours that are resistant to standard radiation. While traditional radiation therapy can target such tumours, there is a higher risk of side effects because of potential damage to the surrounding tissue and organs. More than 4500 Australian from particle therapy.
    [Show full text]
  • Position Paper on Particle Therapy
    POSITION PAPER ON PARTICLE THERAPY FACULTY OF RADIATION ONCOLOGY THE ROYAL AUSTRALIAN AND NEW ZEALAND COLLEGE OF RADIOLOGISTS® Name of document and version: Faculty of Radiation Oncology Position Paper on Particle Therapy Approved by: Faculty of Radiation Oncology Council Date of approval: 23 October 2015 ABN 37 000 029 863 Copyright for this publication rests with The Royal Australian and New Zealand College of Radiologists® The Royal Australian and New Zealand College of Radiologists Level 9, 51 Druitt Street Sydney NSW 2000 Australia Email: [email protected] Website: www.ranzcr.edu.au Telephone: +61 2 9268 9777 Facsimile: +61 2 9268 9799 Disclaimer: The information provided in this document is of a general nature only and is not intended as a substitute for medical or legal advice. It is designed to support, not replace, the relationship that exists between a patient and his/her doctor. CONTENTS Objectives .............................................................................................................. 3 Method .................................................................................................................... 3 About Radiation Oncology ................................................................................... 3 About Proton and Particle Therapy .................................................................... 4 Faculty of Radiation Oncology Position ............................................................. 6 The International Context ....................................................................................
    [Show full text]
  • National Cancer Institute Support for Targeted Alpha-Emitter Therapy
    National Cancer Institute Support for Targeted Alpha-Emitter Therapy Julie Hong National Cancer Institute https://orcid.org/0000-0003-4207-6364 Martin Brechbiel National Cancer Institute Jeff Buchsbaum National Cancer Institute Christie A. Canaria National Cancer Institute C. Norman Coleman National Cancer Institute Freddy E. Escorcia National Cancer Institute Michael Espey National Cancer Institute Charles Kunos National Cancer Institute Frank Lin National Cancer Institute Deepa Narayanan National Cancer Institute Jacek Capala ( [email protected] ) National Cancer Institute Research Article Keywords: Radiopharmaceutical targeted therapy, targeted alpha-emitter therapy, National Cancer Institute Posted Date: June 29th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-650895/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/18 Version of Record: A version of this preprint was published at European Journal of Nuclear Medicine and Molecular Imaging on August 11th, 2021. See the published version at https://doi.org/10.1007/s00259- 021-05503-z. Page 2/18 Abstract Radiopharmaceutical targeted therapy (RPT) has been studied for decades, however, recent clinical trials demonstrating ecacy has helped renew interest in the modality. Recognizing the potential, the National Cancer Institute (NCI) has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials.
    [Show full text]
  • Proton Beam Radiation Therapy – Commercial Medical Policy
    UnitedHealthcare® Commercial Medical Policy Proton Beam Radiation Therapy Policy Number: 2021T0132CC Effective Date: May 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ........................................................................... 1 • Intensity-Modulated Radiation Therapy Documentation Requirements......................................................... 2 • Radiation Therapy: Fractionation, Image-Guidance, Definitions ........................................................................................... 2 and Special Services Applicable Codes .............................................................................. 2 • Stereotactic Body Radiation Therapy and Description of Services ..................................................................... 4 Stereotactic Radiosurgery Clinical Evidence ............................................................................... 4 U.S. Food and Drug Administration ..............................................18 Community Plan Policy References .......................................................................................18 • Proton Beam Radiation Therapy Policy History/Revision Information..............................................23 Medicare Advantage Coverage Summary Instructions for Use .........................................................................23 • Radiologic Therapeutic Procedures Coverage Rationale Note: This policy applies to persons 19 years of age and older. Proton beam radiation
    [Show full text]